Haolong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Haolong Li has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Yongzhe Li
Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
6 shared publications Linlin Cheng
Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences , Beijing , China
3 shared publicationsHaoting Zhan
Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences , Beijing , China
2 shared publicationsSiyu Wang
Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
2 shared publicationsSongxin Yan
Department of Clinical Laboratory State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital Chinese Academy of Medical Science and Peking Union Medical College Beijing China
2 shared publicationsXiaomeng Li
Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College Beijing China
2 shared publications
Latest Publications
- Open Access
The Microbiome in Cancer: Composition, Mechanisms, and Therapeutic Implications
Cancer complexity arises not only from host genetics but also from interactions between the host and microbial communities. However, the field remains fragmented, and a systems‐level framework is needed to guide precision diagnostics and therapy. We develop the “oncobiome” as an integrative framework linking commensal, pathobiont, and tumor‐associated microbial activities to cancer development, progression, and treatment response. We describe how diet, antibiotics, therapy, and environmental factors may shape the shift from microbiome homeostasis to a malignancy‐associated oncobiome. An organ‐specific overview of the oncobiome illustrates how microbial communities interact with systemic microbial, immune, and metabolic networks. Mechanistically, we examine how microbial signals may influence the hallmarks of cancer, including genomic instability, altered tumor metabolism, and immune evasion, as well as epithelial barrier disruption, metastatic progression, and therapeutic resistance. Finally, we assess candidate microbial biomarkers for cancer detection, prognosis, and treatment‐response monitoring, alongside fecal microbiota transplantation, rationally designed microbial consortia, and selected probiotics. We distinguish preliminary anticancer findings from microbiota‐restoration and supportive‐care applications and highlight the need for prospective validation and contamination control. By integrating temporal microbial variation, anatomical niches, and cancer‐relevant functions, this review identifies priorities for development and clinical evaluation of microbiome‐based diagnostics and interventions.
Open AccessThe Microbiome in Cancer: Composition, Mechanisms, and Therapeutic Implications
Cancer complexity arises not only from host genetics but also from interactions between the host and microbial communities. However, the field remains fragmented, and a systems‐level framework is needed to guide precision diagnostics and therapy. We develop the “oncobiome” as an integrative framework linking commensal, pathobiont, and tumor‐associated microbial activities to cancer development, progression, and treatment response. We describe how diet, antibiotics, therapy, and environmental factors may shape the shift from microbiome homeostasis to a malignancy‐associated oncobiome. An organ‐specific overview of the oncobiome illustrates how microbial communities interact with systemic microbial, immune, and metabolic networks. Mechanistically, we examine how microbial signals may influence the hallmarks of cancer, including genomic instability, altered tumor metabolism, and immune evasion, as well as epithelial barrier disruption, metastatic progression, and therapeutic resistance. Finally, we assess candidate microbial biomarkers for cancer detection, prognosis, and treatment‐response monitoring, alongside fecal microbiota transplantation, rationally designed microbial consortia, and selected probiotics. We distinguish preliminary anticancer findings from microbiota‐restoration and supportive‐care applications and highlight the need for prospective validation and contamination control. By integrating temporal microbial variation, anatomical niches, and cancer‐relevant functions, this review identifies priorities for development and clinical evaluation of microbiome‐based diagnostics and interventions.
- Open Access
- 30 July 2023
- Published by Wiley in Journal of Diabetes
- Vol. 15 (11) , 931-943
Antibody response to inactivated COVID‐19 vaccine in patients with type 2 diabetes mellitus after the booster immunization
Background: The immunogenicity of booster inactivated COVID‐19 vaccines in patients with type 2 diabetes mellitus (T2DM) has remained unclear. Our study aims to investigate the antibody response to inactivated COVID‐19 vaccine following booster vaccination in patients with T2DM.Methods: A total of 201 patients with T2DM and 102 healthy controls (HCs) were enrolled. The levels of anti‐SARS‐CoV‐2 total antibodies, anti‐receptor‐binding domain (RBD)‐specific IgG, neutralizing antibody (NAb) toward SARS‐CoV‐2 wild type (WT), and NAb toward SARS‐CoV‐2 Omicron BA.4/5 subvariant were measured to evaluate the vaccine‐induced immunological responses.Results: The titers of anti‐RBD‐specific IgG (p = 0.018) and inhibition rates of NAb toward WT (p = 0.007) were significantly decreased in patients with T2DM compared to HCs after booster vaccination for more than 6 months. Both HCs and patients with T2DM showed poor resistance against BA.4/5 due to the detected inhibition rates being lower than the positive threshold. The levels of anti‐RBD‐specific IgG were positively associated with the proportions of CD3+CD4−CD8− T cells (p = 0.045), and patients with T2DM who had anti‐RBD‐specific IgG positivity showed higher proportions of CD3+CD4−CD8− T cells compared to those negative (p = 0.005).Conclusions: Patients with T2DM showed impaired antibody responses after booster vaccination for more than 6 months. Decreased anti‐BA.4/5 responses give rise to the possibility of breakthrough infections for both patients with T2DM and HCs.
- 30 July 2023
- Published by Wiley in Journal of Diabetes
- Vol. 15 (11) , 931-943
Open AccessAntibody response to inactivated COVID‐19 vaccine in patients with type 2 diabetes mellitus after the booster immunization
Background: The immunogenicity of booster inactivated COVID‐19 vaccines in patients with type 2 diabetes mellitus (T2DM) has remained unclear. Our study aims to investigate the antibody response to inactivated COVID‐19 vaccine following booster vaccination in patients with T2DM.Methods: A total of 201 patients with T2DM and 102 healthy controls (HCs) were enrolled. The levels of anti‐SARS‐CoV‐2 total antibodies, anti‐receptor‐binding domain (RBD)‐specific IgG, neutralizing antibody (NAb) toward SARS‐CoV‐2 wild type (WT), and NAb toward SARS‐CoV‐2 Omicron BA.4/5 subvariant were measured to evaluate the vaccine‐induced immunological responses.Results: The titers of anti‐RBD‐specific IgG (p = 0.018) and inhibition rates of NAb toward WT (p = 0.007) were significantly decreased in patients with T2DM compared to HCs after booster vaccination for more than 6 months. Both HCs and patients with T2DM showed poor resistance against BA.4/5 due to the detected inhibition rates being lower than the positive threshold. The levels of anti‐RBD‐specific IgG were positively associated with the proportions of CD3+CD4−CD8− T cells (p = 0.045), and patients with T2DM who had anti‐RBD‐specific IgG positivity showed higher proportions of CD3+CD4−CD8− T cells compared to those negative (p = 0.005).Conclusions: Patients with T2DM showed impaired antibody responses after booster vaccination for more than 6 months. Decreased anti‐BA.4/5 responses give rise to the possibility of breakthrough infections for both patients with T2DM and HCs.
- Open Access
SARS-CoV-2 Vaccine Uptake among Patients with Chronic Liver Disease: A Cross-Sectional Analysis in Hebei Province, China
Chronic liver disease (CLD) patients have higher mortality and hospitalization rates after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to explore SARS-CoV-2 vaccine perceptions, side effects, factors associated with nonvaccination and attitudes toward fourth-dose vaccine among CLD patients. The differences between vaccinated and unvaccinated groups among 1491 CLD patients and the risk factors associated with nonvaccination status were analyzed. In total, 1239 CLD patients were immunized against SARS-CoV-2. CLD patients have a high level of trust in the government and clinicians and were likely to follow their recommendations for vaccination. Reasons reported for nonvaccination were mainly concerns about the vaccines affecting their ongoing treatments and the fear of adverse events. However, only 4.84% of patients reported mild side effects. Risk factors influencing nonvaccination included being older in age, having cirrhosis, receiving treatments, having no knowledge of SARS-CoV-2 vaccine considerations and not receiving doctors’ positive advice on vaccination. Furthermore, 20.6% of completely vaccinated participants refused the fourth dose because they were concerned about side effects and believed that the complete vaccine was sufficiently protective. Our study proved that SARS-CoV-2 vaccines were safe for CLD patients. Our findings suggest that governments and health workers should provide more SARS-CoV-2 vaccination information and customize strategies to improve vaccination coverage and enhance vaccine protection among the CLD population.
Open AccessSARS-CoV-2 Vaccine Uptake among Patients with Chronic Liver Disease: A Cross-Sectional Analysis in Hebei Province, China
Chronic liver disease (CLD) patients have higher mortality and hospitalization rates after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to explore SARS-CoV-2 vaccine perceptions, side effects, factors associated with nonvaccination and attitudes toward fourth-dose vaccine among CLD patients. The differences between vaccinated and unvaccinated groups among 1491 CLD patients and the risk factors associated with nonvaccination status were analyzed. In total, 1239 CLD patients were immunized against SARS-CoV-2. CLD patients have a high level of trust in the government and clinicians and were likely to follow their recommendations for vaccination. Reasons reported for nonvaccination were mainly concerns about the vaccines affecting their ongoing treatments and the fear of adverse events. However, only 4.84% of patients reported mild side effects. Risk factors influencing nonvaccination included being older in age, having cirrhosis, receiving treatments, having no knowledge of SARS-CoV-2 vaccine considerations and not receiving doctors’ positive advice on vaccination. Furthermore, 20.6% of completely vaccinated participants refused the fourth dose because they were concerned about side effects and believed that the complete vaccine was sufficiently protective. Our study proved that SARS-CoV-2 vaccines were safe for CLD patients. Our findings suggest that governments and health workers should provide more SARS-CoV-2 vaccination information and customize strategies to improve vaccination coverage and enhance vaccine protection among the CLD population.
- Open Access
- 8 February 2023
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 212 (3) , 199-211
Progress and challenges in the use of blood biomarkers in relapsing polychondritis
Summary: Relapsing polychondritis (RP) is a rare inflammatory disease with significant individual heterogeneity that involves systemic organs. The diagnosis of RP mainly depends on the clinical manifestations; currently, there are no molecular biomarkers routinely evaluated in clinical practice. Biomarkers have diagnostic or monitoring values and can predict response to treatment or the disease course. Over the years, many biomarkers have been proposed to facilitate diagnosis and prognosis. Unfortunately, ideal biomarkers to diagnose RP have not yet been discovered. Most of the molecular biomarkers in RP are immunological biomarkers, with autoantibodies and proteins related to cartilage damage in the blood being the most common. Alterations in some genes (HLA typing and UBA1 somatic mutation) were detected in patients with RP, which could serve as a potential biomarker for the diagnosis of RP. Moreover, proinflammatory cytokines and lymphocyte levels, and certain laboratory tests, have certain values of RP diagnosis and disease activity assessment but lack specificity and sensitivity. This review describes the different types of biomarkers and their clinical correlation with respect to the diagnosis of RP and disease activity. Research on biomarkers and disease pathology is ongoing to identify the ideal biomarkers that are sensitive and specific for RP.
- 8 February 2023
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 212 (3) , 199-211
Open AccessProgress and challenges in the use of blood biomarkers in relapsing polychondritis
Summary: Relapsing polychondritis (RP) is a rare inflammatory disease with significant individual heterogeneity that involves systemic organs. The diagnosis of RP mainly depends on the clinical manifestations; currently, there are no molecular biomarkers routinely evaluated in clinical practice. Biomarkers have diagnostic or monitoring values and can predict response to treatment or the disease course. Over the years, many biomarkers have been proposed to facilitate diagnosis and prognosis. Unfortunately, ideal biomarkers to diagnose RP have not yet been discovered. Most of the molecular biomarkers in RP are immunological biomarkers, with autoantibodies and proteins related to cartilage damage in the blood being the most common. Alterations in some genes (HLA typing and UBA1 somatic mutation) were detected in patients with RP, which could serve as a potential biomarker for the diagnosis of RP. Moreover, proinflammatory cytokines and lymphocyte levels, and certain laboratory tests, have certain values of RP diagnosis and disease activity assessment but lack specificity and sensitivity. This review describes the different types of biomarkers and their clinical correlation with respect to the diagnosis of RP and disease activity. Research on biomarkers and disease pathology is ongoing to identify the ideal biomarkers that are sensitive and specific for RP.
- 3 April 2022
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 96 (1) , e13166
Imbalanced distribution of group 2 innate lymphoid cells (ILCs) and ILC precursors in peripheral blood of patients with primary biliary cholangitis
Innate lymphoid cells (ILCs), a novel group of innate immune cells, play a key role in the early immune response via rapidly reacting to signals expressed by tissue‐resident cells. ILCs contribute to some autoimmune diseases. We aim to investigate the proportions of circulating ILC subgroups in patients with primary biliary cholangitis (PBC). Overall, 48 patients with PBC and 24 healthy controls (HCs) were enrolled. Circulating ILCs and cytokine production were detected by flow cytometry. The proportions of total ILCs, ILC precursors (ILCPs) and ILCP/ILC2 ratio increased and that of ILC2s decreased in patients with PBC. ILC2 proportion was negatively correlated with gamma‐glutamyl transpeptidase (GGT), alanine aminotransferase (ALT) and aspartate aminotransferase (AST). The proportion of ILCPs and ILCP/ILC2 ratio were positively correlated with alkaline phosphatase, GGT, ALT and AST. ILC2 proportion was significantly decreased in the ursodeoxycholic acid (UDCA) ‐non‐responder group compared with the UDCA‐responder group, whereas the proportion of ILCPs and ILCP/ILC2 were ratio significantly increased. The proportions of CD38+ILC2s, CD38+ILCPs, CD45RO+ILC2s and CD45RO+ILCPs were significantly higher in patients with PBC than in HCs. Levels of IL‐17A producing ILCs were higher in patients with PBC than in HCs. PBC is accompanied by alterations in circulating ILCs. The proportions of ILC2s, ILCPs, and ILCP/ILC2 ratio were associated with the PBC disease activity. The proportions of ILCPs and ILCP/ILC2 ratio may reflect the UDCA treatment failure in patients with PBC. ILC2s and ILCPs from patients with PBC get activated, these cells may be involved in the pathogenesis of PBC.
- 3 April 2022
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 96 (1) , e13166
Imbalanced distribution of group 2 innate lymphoid cells (ILCs) and ILC precursors in peripheral blood of patients with primary biliary cholangitis
Innate lymphoid cells (ILCs), a novel group of innate immune cells, play a key role in the early immune response via rapidly reacting to signals expressed by tissue‐resident cells. ILCs contribute to some autoimmune diseases. We aim to investigate the proportions of circulating ILC subgroups in patients with primary biliary cholangitis (PBC). Overall, 48 patients with PBC and 24 healthy controls (HCs) were enrolled. Circulating ILCs and cytokine production were detected by flow cytometry. The proportions of total ILCs, ILC precursors (ILCPs) and ILCP/ILC2 ratio increased and that of ILC2s decreased in patients with PBC. ILC2 proportion was negatively correlated with gamma‐glutamyl transpeptidase (GGT), alanine aminotransferase (ALT) and aspartate aminotransferase (AST). The proportion of ILCPs and ILCP/ILC2 ratio were positively correlated with alkaline phosphatase, GGT, ALT and AST. ILC2 proportion was significantly decreased in the ursodeoxycholic acid (UDCA) ‐non‐responder group compared with the UDCA‐responder group, whereas the proportion of ILCPs and ILCP/ILC2 were ratio significantly increased. The proportions of CD38+ILC2s, CD38+ILCPs, CD45RO+ILC2s and CD45RO+ILCPs were significantly higher in patients with PBC than in HCs. Levels of IL‐17A producing ILCs were higher in patients with PBC than in HCs. PBC is accompanied by alterations in circulating ILCs. The proportions of ILC2s, ILCPs, and ILCP/ILC2 ratio were associated with the PBC disease activity. The proportions of ILCPs and ILCP/ILC2 ratio may reflect the UDCA treatment failure in patients with PBC. ILC2s and ILCPs from patients with PBC get activated, these cells may be involved in the pathogenesis of PBC.
- Open Access
- 13 March 2021
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 24 (5) , 633-646
Diagnostic value of anti‐citrullinated α‐enolase peptide 1 antibody in patients with rheumatoid arthritis: A systematic review and meta‐analysis
Aim To evaluate the diagnostic value of anti‐citrullinated α‐enolase peptide 1 (anti‐CEP 1) antibody in patients with rheumatoid arthritis (RA) by conducting a systematic review and meta‐analysis. Methods The PubMed, Web of Science, Embase, Scopus, and Cochrane Library databases were searched for relevant studies published until September 23, 2020. A bivariate mixed‐effects model was used to calculate the diagnostic indices from primary data of eligible studies. We performed meta‐regression and subgroup analysis to explore the sources of heterogeneity. Results Twenty‐four articles, with a total of 17 380 patients with RA and 7505 control participants, met the criteria for inclusion in the meta‐analysis. The pooled sensitivity, specificity, and positive and negative likelihood ratios for the anti‐CEP 1 antibody were 44% (95% CI: 38%‐51%), 97% (95% CI: 96%‐98%), and 14.81 (95% CI: 10.66‐20.57) and 0.57 (95% CI: 0.52‐0.64), respectively. The pooled positive and negative predictive values were 0.96 (95% CI: 0.95‐0.97) and 0.53 (95% CI: 0.43‐0.63), respectively. The area under the summary receiver operating characteristic curve was 0.86. Meta‐regression indicated that the anti‐CEP 1 antibody detection method may be a source of heterogeneity. The subgroup analysis of the group in which the anti‐CEP 1 antibody was detected by using a commercial enzyme‐linked immunosorbent assay (ELISA) kit had a sensitivity of 59% (95% CI: 50%‐68%) and a specificity of 93% (95% CI: 85%‐97%). Conclusions The anti‐CEP 1 antibody had moderate RA diagnostic value with relatively low sensitivity and high specificity. An ELISA may increase the RA diagnostic sensitivity.
- 13 March 2021
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 24 (5) , 633-646
Open AccessDiagnostic value of anti‐citrullinated α‐enolase peptide 1 antibody in patients with rheumatoid arthritis: A systematic review and meta‐analysis
Aim To evaluate the diagnostic value of anti‐citrullinated α‐enolase peptide 1 (anti‐CEP 1) antibody in patients with rheumatoid arthritis (RA) by conducting a systematic review and meta‐analysis. Methods The PubMed, Web of Science, Embase, Scopus, and Cochrane Library databases were searched for relevant studies published until September 23, 2020. A bivariate mixed‐effects model was used to calculate the diagnostic indices from primary data of eligible studies. We performed meta‐regression and subgroup analysis to explore the sources of heterogeneity. Results Twenty‐four articles, with a total of 17 380 patients with RA and 7505 control participants, met the criteria for inclusion in the meta‐analysis. The pooled sensitivity, specificity, and positive and negative likelihood ratios for the anti‐CEP 1 antibody were 44% (95% CI: 38%‐51%), 97% (95% CI: 96%‐98%), and 14.81 (95% CI: 10.66‐20.57) and 0.57 (95% CI: 0.52‐0.64), respectively. The pooled positive and negative predictive values were 0.96 (95% CI: 0.95‐0.97) and 0.53 (95% CI: 0.43‐0.63), respectively. The area under the summary receiver operating characteristic curve was 0.86. Meta‐regression indicated that the anti‐CEP 1 antibody detection method may be a source of heterogeneity. The subgroup analysis of the group in which the anti‐CEP 1 antibody was detected by using a commercial enzyme‐linked immunosorbent assay (ELISA) kit had a sensitivity of 59% (95% CI: 50%‐68%) and a specificity of 93% (95% CI: 85%‐97%). Conclusions The anti‐CEP 1 antibody had moderate RA diagnostic value with relatively low sensitivity and high specificity. An ELISA may increase the RA diagnostic sensitivity.
- Open Access
The change pattern and significance of IgM and IgG in the progress of COVID-19 disease
Background: To investigate the significance of IgM and IgG in the progress of COVID-19. Method: A multicenter cross-sectional study conducted in suspected and confirmed patients from four hospitals of China and a cohort study to identify the change pattern and significance in the process of COVID-19 disease. Results: A total of 571 patients were enrolled in the cross-sectional study, including 235 confirmed SARS-CoV-2 infection with 91.9% patients IgG positive and 92.3% IgM positive. 30 patients diagnosed with SARS-CoV-2 infection were enrolled in the cohort study for flowing-up in 20 days. The peak of IgM and IgG reached in 10 th and 20 th day separately after symptom onset. The relationship between clinical classification and serological antibodies were analysed. The positive rate of COVID-19 IgG and IgM increased along with the clinical classification and the delay of treatment time. Conclusion: We demonstrated the kinetics of IgM and IgG SARS-CoV-2 antibody in COVID-19 patients, which may contribute to explain the results of IgM and IgG SARS-CoV-2 antibody test and predict the prognosis of COVID-19.
Open AccessThe change pattern and significance of IgM and IgG in the progress of COVID-19 disease
Background: To investigate the significance of IgM and IgG in the progress of COVID-19. Method: A multicenter cross-sectional study conducted in suspected and confirmed patients from four hospitals of China and a cohort study to identify the change pattern and significance in the process of COVID-19 disease. Results: A total of 571 patients were enrolled in the cross-sectional study, including 235 confirmed SARS-CoV-2 infection with 91.9% patients IgG positive and 92.3% IgM positive. 30 patients diagnosed with SARS-CoV-2 infection were enrolled in the cohort study for flowing-up in 20 days. The peak of IgM and IgG reached in 10 th and 20 th day separately after symptom onset. The relationship between clinical classification and serological antibodies were analysed. The positive rate of COVID-19 IgG and IgM increased along with the clinical classification and the delay of treatment time. Conclusion: We demonstrated the kinetics of IgM and IgG SARS-CoV-2 antibody in COVID-19 patients, which may contribute to explain the results of IgM and IgG SARS-CoV-2 antibody test and predict the prognosis of COVID-19.